When I last wrote about TG Therapeutics ( TGTX ) in August, I noted a couple of softer quarters of Briumvi sales growth. I rated TGTX a hold at that time, as there was room for a TV campaign to aid sales nearer-term, withScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure:I/we have a benef ...

Group 1 - The core viewpoint indicates that TG Therapeutics (TGTX) experienced softer sales growth for Briumvi in recent quarters, leading to a hold rating due to potential for a TV campaign to boost near-term sales [1] Group 2 - The article emphasizes the importance of trading around significant events such as trial results and NDA/BLA approvals in the biotech sector [1]

Core Insights - Roche's fenebrutinib demonstrated "unprecedented" test results for multiple sclerosis, impacting TG Therapeutics negatively [1][2] - Roche's stock increased by over 3% to $43.33, while TG Therapeutics' stock fell more than 5% to $30.53, reaching a two-month low [2] - Fenebrutinib showed significantly fewer relapses compared to teriflunomide in relapsing multiple sclerosis patients [3] - In primary progressive MS, fenebrutinib slowed disability progression comparably to Roche's Ocrevus, the only approved treatment for this condition [4] Roche's Competitive Position - Roche's fenebrutinib uses a different mechanism than TG Therapeutics' Briumvi, targeting BTK, which is involved in immune response to inflammation [7] - Roche's stock performance improved, gapping above its 50-day moving average following the news [7] TG Therapeutics' Market Performance - Briumvi's sales grew by at least double-digit percentages year-over-year, with a notable 84% increase to $152.9 million in Q3 [6] - Despite the sales growth, Briumvi still lags behind Ocrevus in overall sales [6] - TG Therapeutics maintains a strong IBD Digital Composite Rating of 97, ranking in the top 3% of stocks for performance [8]

Core Insights - TG Therapeutics reported adjusted earnings of $2.43 per share and $161.7 million in sales for Q3, significantly exceeding analyst expectations of $0.22 earnings per share and $152.1 million in sales [1][2] - The earnings beat was primarily attributed to a one-time tax benefit of $365 million, which, if excluded, would have resulted in earnings closer to $0.15 per share [2] - The company raised its full-year sales guidance to $600 million, with $585 million expected from U.S. sales of its multiple sclerosis drug Briumvi [3] Financial Performance - Q3 adjusted earnings: $2.43 per share [1] - Q3 sales: $161.7 million [1] - Analyst expectations: $0.22 earnings per share and $152.1 million in sales [2] - Previous year Q3 earnings: $0.02 per share and $83.9 million in sales [2] - Revised full-year sales guidance: $600 million [3] Market Reaction - TG Therapeutics stock increased by 4.4% to $36.30 in premarket trading [3] - Shares are trading slightly above their 50-day moving average [3] Ratings and Upgrades - TG Therapeutics received an upgrade in its IBD SmartSelect Composite Rating from 94 to 97 [4][7] - The company is now part of an elite list of stocks with a composite rating above 95 [7]

Core Insights - TG Therapeutics, Inc. (TGTX) reported its Q3 earnings and business updates, with the stock experiencing a decline of approximately 4% in trading on the announcement day [1]. Financial Performance - The article highlights the financials of TG Therapeutics, indicating a focus on the company's earnings and business updates for Q3 [1]. Industry Context - The article emphasizes the importance of staying updated on stocks within the biotech, pharma, and healthcare sectors, suggesting that understanding key trends and catalysts is crucial for investors [1].

Core Insights - TG Therapeutics, Inc. (TGTX) reported its Q3 earnings and business updates, with the stock experiencing a decline of approximately 4% in trading on the announcement day [1]. Financial Performance - The article highlights the financials of TG Therapeutics, indicating a focus on the company's earnings and business updates for Q3 [1]. Industry Context - The article emphasizes the importance of staying updated on stocks within the biotech, pharma, and healthcare sectors, suggesting that understanding key trends and catalysts is crucial for investors [1].

Core Insights - TG Therapeutics reported a significant earnings miss for Q2 2025, with earnings of 17 cents per share compared to the Zacks Consensus Estimate of 32 cents, although revenues increased by nearly 92% year over year to $141.1 million, driven by strong demand for Briumvi [2][4] Financial Performance - Briumvi's net product sales reached $138.8 million in the U.S. for Q2 2025, marking a 91% year-over-year increase and a 16% sequential increase [4] - Total revenues included $2.3 million from license, milestone, royalty, and other revenues, up from $0.9 million in the same quarter last year [4] - Research and development expenses rose approximately 83.3% year over year to $27.5 million, primarily due to increased manufacturing costs for Briumvi's subcutaneous formulation [5] - Selling, general, and administrative expenses totaled $43.5 million, up nearly 36.8% from the previous year, attributed to higher commercialization costs for Briumvi [5] - As of June 30, 2025, TG Therapeutics had cash and investments totaling $278.9 million, slightly up from $276.2 million at the end of Q1 2025 [6] Guidance and Estimates - The company raised its full-year revenue guidance for 2025 to approximately $585 million, up from the previous estimate of $575 million, with net product sales of Briumvi expected to be between $570 million and $575 million in the U.S. [7] - Operating expenses for the full year are projected to remain around $300 million, unchanged from prior guidance [8] - Following the earnings release, there has been a downward trend in fresh estimates, with the consensus estimate shifting down by 5.38% [9] Stock Performance and Outlook - TG Therapeutics currently holds a Zacks Rank 3 (Hold), indicating an expectation of an in-line return in the coming months [11] - The company has a strong Growth Score of A but is lagging in Momentum with a score of F, resulting in an overall VGM Score of D [10]

Company Overview - TG Therapeutics (NASDAQ: TGTX) is a commercial stage biotech company focused on Briumvi, a treatment for multiple sclerosis [1] Investment Strategy - The investment approach involves careful analysis of earnings reports to identify potential growth opportunities, with past successes including companies like OPRX, OTRK, FUBO, and PLUG [1]

Financial Performance - TG Therapeutics reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the consensus of 17 cents [1] - The company reported sales of $120.86 million, up from $63.47 million a year ago, beating the consensus of $118.43 million [1] Product Performance - Briumvi's U.S. net sales reached $119.7 million, demonstrating growing confidence in the treatment and increasing adoption by healthcare providers [2][3] - The company presented five-year data from the ULTIMATE I & II Phase 3 trials, showing that 92% of patients were free from disability progression after five years, with an annualized relapse rate of 0.02 during year 5 [4] - No new safety signals emerged over five years of continuous treatment, with no observed cases of progressive multifocal leukoencephalopathy (PML) [4] Future Guidance - TG Therapeutics raised Briumvi's U.S. net product revenue target to $560 million for fiscal 2025 from $525 million in prior guidance [5] - The total global revenue target was raised to $575 million from prior guidance of $540 million [5] - Briumvi's U.S. net product revenue is expected to be $135 million in the second quarter of 2025 [5] Stock Performance - TGTX stock was down 13.2% at $37.68 on Monday [6]

Core Insights - TG Therapeutics reported a significant increase in revenue and achieved profitability, but the stock price fell sharply due to investor disappointment [1][4][7] Revenue Performance - The company's revenue for the first quarter was nearly $121 million, almost double the $63.5 million from the same period in 2024, driven primarily by Briumvi sales [2][6] - Analysts had a collective revenue estimate of $117 million, indicating that the actual revenue exceeded expectations [4] Profitability - TG Therapeutics posted a net profit of just over $5 million, or $0.03 per share, compared to an almost $11 million loss in the first quarter of 2024 [4] - The consensus estimate for earnings per share was $0.16, suggesting that the actual profit fell short of analyst expectations [4][7] Pipeline Developments - The company is conducting two phase 1 trials for Briumvi: one for subcutaneous use in relapsing MS patients and another for myasthenia gravis [5] - Additionally, TG is developing a CAR T cell therapy, azercabtagene zapreleucel, which is currently in enrollment for a phase 1 trial [5] Guidance Update - TG Therapeutics raised its guidance for domestic Briumvi sales in 2025 to $560 million, up from a previous estimate of $525 million [6] - Overall revenue guidance was also increased to $575 million from $540 million [6]